Alain Moreau on Myalgic Encephalomyelitis (ME/CFS) Research and Diagnosis

Understanding Myalgic Encephalomyelitis (ME/CFS)

• 💡 ME, also known as chronic fatigue syndrome, affects over half a million people in France, with cases increasing post-Covid-19.
• 🧠 Alain Moreau, a leading scientist, discusses advancements in ME research, focusing on epigenetics rather than traditional genetics.

Diagnostic Advancements

• 🔬 Research has identified circulating microRNA signatures in ME patients, leading to the development of the first diagnostic test.
• ✅ This blood test allows for repeatable confirmation of ME diagnosis and can differentiate it from conditions like fibromyalgia, which can co-occur in up to 50% of cases.
• ⏱️ The diagnostic tools aim to expedite diagnosis, reduce medical uncertainty for patients, and aid in screening for therapeutic solutions.

Nature of the Disease

• ⚠️ ME is confirmed as a physical disease, not a somatic condition, affecting systems like vascular tone, sleep, immune function, and the neuroendocrine system.
• 🧠 Deep phenotyping reveals changes in the brain, including altered oxygen levels and cognitive issues like memory problems, which can be monitored, especially during provocation maneuvers that induce post-exertional malaise.

Research Priorities and Future Directions

• 🧩 Patients are not homogenous; at least five subgroups of ME patients have been identified, each associated with predominant symptoms like brain fog or endothelial vascular dysfunction.
• 🎯 The priority is to recognize these subgroups early to develop precision medicine approaches, potentially repurposing existing drugs to target specific mechanisms.
• 💰 Further research requires additional funding from the private sector to translate diagnostic panels from the lab to clinical practice and to conduct new clinical trials based on precision medicine principles.
• 🚀 The ultimate goal is to find long-term solutions that prevent patient crashes and bring useful treatments to a wider patient population.